Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29234163 | 0.99 | MEN1 (0.56) | MEN1KMT2ANPSR1CA1CA2 | |
| SCHEMBL9633964 | 0.95 | MEN1 (0.57) | MEN1KMT2ANPSR1CA1CA2 | |
| SCHEMBL27610472 | 0.87 | NPSR1 (0.54) | MEN1KMT2ANPSR1CA1CA2 | |
| SCHEMBL22788750 | 0.87 | MEN1 (0.57) | MEN1KMT2ANPSR1CA1CA2 | |
| SCHEMBL29234309 | 0.86 | HTT (0.55) | MEN1KMT2ANPSR1CA1CA2 | |
| SCHEMBL21527984 | 0.86 | MEN1 (0.53) | MEN1KMT2ANPSR1CA1CA2 | |
| SCHEMBL5542172 | 0.86 | NPSR1 (0.56) | MEN1KMT2ANPSR1CA1CA2 | |
| SCHEMBL27629467 | 0.86 | SIGMAR1 (0.56) | MEN1KMT2ANPSR1CA1CA2 | |
| SCHEMBL5154279 | 0.85 | MEN1 (0.58) | MEN1KMT2ANPSR1CA1CA2 | |
| SCHEMBL5541709 | 0.85 | MEN1 (0.52) | MEN1KMT2ANPSR1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| EP-3939972-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | Molecular Insight Pharmaceuticals, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3545978-B1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARM INC (US) | 2021-09-08 | — | — | EP | disclosed |
| US-10898598-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3545978-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | Molecular Insight Pharmaceuticals, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3300746-B1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARM INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190134237-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10201624-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10086096-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170296683-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| EP-2943227-B1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARM INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20160346410-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-9447121-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20140255306-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA2, PSMA5, PSMA1 | MEN1 104/4885KMT2A 1018/4885NPSR1 421/4885 |
| US-10898598-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | MEN1 104/4885KMT2A 1018/4885NPSR1 421/4885 |
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | MEN1 104/4885KMT2A 1018/4885NPSR1 421/4885 |
| US-20170296683-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA2, PSMA5, PSMA1 | MEN1 104/4885KMT2A 1018/4885NPSR1 421/4885 |
| US-20160346410-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA5, PSMA2, PSMA1 | MEN1 141/4885KMT2A 1288/4885NPSR1 679/4885 |
| US-20140255306-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA5, PSMA2, PSMA1 | MEN1 141/4885KMT2A 1288/4885NPSR1 679/4885 |
| US-10086096-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | MEN1 104/4885KMT2A 1018/4885NPSR1 421/4885 |
| US-10201624-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA5, PSMA2, PSMA1 | MEN1 141/4885KMT2A 1288/4885NPSR1 679/4885 |
| US-20190134237-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA2, PSMA5, PSMA1 | MEN1 104/4885KMT2A 1018/4885NPSR1 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.